{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:05:38Z","timestamp":1788505538491,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"DOI":"10.3389\/fped.2017.00007","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T03:32:19Z","timestamp":1485315139000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease"],"prefix":"10.3389","volume":"5","author":[{"given":"Wael","family":"El-Matary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmail","family":"Abej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vini","family":"Deora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,1,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/jclinpath-2012-200901","article-title":"Faecal markers of gastrointestinal inflammation","volume":"65","author":"Sherwood","year":"2012","journal-title":"J Clin Pathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.gtc.2012.01.007","article-title":"Fecal markers: calprotectin and lactoferrin","volume":"41","author":"Abraham","year":"2012","journal-title":"Gastroenterol Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/gut.2008.170019","article-title":"Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage","volume":"58","author":"Foell","year":"2009","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/j.1440-1746.2011.06846.x","article-title":"Update of fecal markers of inflammation in inflammatory bowel disease","volume":"26","author":"Judd","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1155\/2012\/984575","article-title":"Inflammatory bowel disease: a Canadian burden of illness review","volume":"26","author":"Rocchi","year":"2012","journal-title":"Can J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/01.mib.0000228358.25364.8b","article-title":"Challenges in pediatric inflammatory bowel disease","volume":"12","author":"Bousvaros","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/apa.13026","article-title":"Anti-Saccharomyces cerevisiae antibody titres correlate well with disease activity in children with Crohn\u2019s disease","volume":"104","author":"El-Matary","year":"2015","journal-title":"Acta Paediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.cgh.2014.06.020","article-title":"Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission","volume":"12","author":"Guardiola","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ibd.20490","article-title":"Crohn\u2019s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn\u2019s disease activity index and endoscopic findings","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.crohns.2011.11.002","article-title":"Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF na\u00efve patients with ulcerative colitis","volume":"6","author":"De Vos","year":"2012","journal-title":"J Crohns Colitis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.MPG.0000163736.30261.82","article-title":"Inflammatory bowel disease in children and adolescents: recommendations for diagnosis \u2013 the Porto criteria","volume":"41","author":"IBD Working Group of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)","year":"2005","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/00005176-199105000-00005","article-title":"Development and validation of a pediatric Crohn\u2019s disease activity index","volume":"12","author":"Hyams","year":"1991","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00054725-200502000-00013","article-title":"A review of activity indices and end points for clinical trials in children with Crohn\u2019s disease","volume":"11","author":"Griffiths","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"B15","doi-asserted-by":"crossref","first-page":"2483261","DOI":"10.1155\/2016\/2483261","article-title":"The utility of fecal calprotectin in the real-world clinical care of patients with inflammatory bowel disease","volume":"2016","author":"Abej","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1155\/2015\/950286","article-title":"Fecal calprotectin use in inflammatory bowel disease and beyond: a mini-review","volume":"29","author":"Alibrahim","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/ibd.22917","article-title":"Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease","volume":"18","author":"D\u2019Haens","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/00005176-200102000-00015","article-title":"Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease","volume":"32","author":"Bunn","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.dld.2008.01.017","article-title":"Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease","volume":"40","author":"Canani","year":"2008","journal-title":"Dig Liver Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ajg.2009.545","article-title":"Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn\u2019s disease (SES-CD) than CRP, blood leukocytes, and the CDAI","volume":"105","author":"Schoepfer","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MIB.0b013e3182810066","article-title":"Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes","volume":"19","author":"Schoepfer","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/gut.2004.043406","article-title":"Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn\u2019s disease","volume":"54","author":"Costa","year":"2005","journal-title":"Gut"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1002\/ibd.22896","article-title":"Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control","volume":"18","author":"van Rheenen","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/gut.2010.211755","article-title":"Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response","volume":"59","author":"Turner","year":"2010","journal-title":"Gut"},{"issue":"Suppl 1","key":"B25","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(14)62888-2","article-title":"An overview of the impact of fecal calprotectin testing in the management of patients within the gastroenterology outpatient clinic in a general hospital","volume":"146","author":"Eccles","year":"2014","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.cgh.2014.03.035","article-title":"Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis","volume":"12","author":"Osterman","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/2050640614560785","article-title":"Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: a prospective, randomized, controlled study","volume":"3","author":"Lasson","year":"2015","journal-title":"United European Gastroenterol J"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fped.2017.00007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T08:59:30Z","timestamp":1498381170000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fped.2017.00007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,25]]},"references-count":27,"URL":"https:\/\/doi.org\/10.3389\/fped.2017.00007","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,25]]}}}